Targeted Genetics warned last week that it will begin shutting down its operations if it is unable to secure additional funding during the second quarter.

"If we are not successful in extending our cash horizon by the end of June 2009, we plan to begin the process of ceasing operations, seeking bankruptcy protection, or otherwise winding up our business," President and CEO Susan Robinson said during the firm's first-quarter conference call.

As of March 31, Targeted Genetics had cash and cash equivalents totaling $3.9 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.